Skip to Content

Neoadjuvant Enhertu and HER2-low breast cancer – Overall response rate of 75%

Patients with localized, hormone receptor-positive, HER2-low breast cancer treated with Enhertu, trastuzumab deruxtecan, in the neoadjuvant setting had an overall response rate of 75% in the absence of anastrozole and 63% in combination with anastrozole.

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top